The global live biotherapeutic products (LBP) and microbiome contract development and manufacturing organization (CDMO) market is experiencing rapid growth, driven by increasing research in microbiome-based therapies and rising demand for outsourcing pharmaceutical development. Live biotherapeutics are emerging as a promising approach for treating a wide range of diseases, including gastrointestinal disorders, metabolic conditions, and immune-related diseases.

Market Size and Forecast

The global live biotherapeutic products and microbiome CDMO market was valued at USD 2.48 billion in 2024 and is projected to grow from USD 2.93 billion in 2025 to USD 9.84 billion by 2033, registering a CAGR of 18.2% during the forecast period (2025–2033). The base year considered for the study is 2024, with the forecast period spanning from 2025 to 2033.

Unlock Full Report Insights and Strategic Analysis- https://straitsresearch.com/report/live-biotherapeutic-products-and-microbiome-cdmo-market

Key Highlights

• Largest Region: North America dominates the global market due to strong research infrastructure and significant investments in microbiome-based therapeutics.

• Fastest Growing Region: Asia-Pacific is expected to register the highest CAGR, driven by expanding biotechnology sectors and increasing outsourcing activities.

• Largest Segment (By Service Type): Contract manufacturing holds the largest market share due to increasing demand for large-scale production of live biotherapeutics.

• Fastest Growing Segment (By Service Type): Contract development is projected to grow at a notable CAGR due to rising R&D activities in microbiome therapies.

• Largest Segment (By Application): Gastrointestinal disorders segment dominates the market due to the high prevalence of gut-related diseases.

Market Dynamics

Drivers:
The increasing focus on microbiome research and the growing prevalence of chronic diseases are key drivers of the market. Pharmaceutical and biotechnology companies are increasingly outsourcing development and manufacturing activities to CDMOs to reduce costs and accelerate product development timelines. Additionally, advancements in genomics and biotechnology are enabling the development of innovative live biotherapeutic products, further boosting market growth.

Restraints and Opportunities:
However, regulatory complexities and challenges associated with the development and commercialization of live biotherapeutics may hinder market growth. High costs and technical difficulties in manufacturing microbial-based products also pose challenges. Despite these restraints, the market presents significant opportunities with increasing investments in microbiome research and rising demand for personalized medicine. Expanding collaborations between biotech firms and CDMOs are expected to drive future growth.

Top Market Players

• Lonza Group AG

• Catalent, Inc.

• Thermo Fisher Scientific Inc.

• Charles River Laboratories International, Inc.

• Samsung Biologics Co., Ltd.

• Recipharm AB

• Evotec SE

• Arranta Bio

• Assembly Biosciences, Inc.

• Enterome SA

Download the Free Sample Report - https://straitsresearch.com/report/live-biotherapeutic-products-and-microbiome-cdmo-market/request-sample

Market Segmentation

By Service Type

• Contract Development

• Contract Manufacturing

By Application

• Gastrointestinal Disorders

• Metabolic Disorders

• Infectious Diseases

• Others

By End-User

• Pharmaceutical Companies

• Biotechnology Companies

• Research Institutes

By Region

• North America

• Europe

• Asia-Pacific

• Middle East and Africa

• Latin America

About Us

Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

Contact Us

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)